Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. (Q48599660)
Jump to navigation
Jump to search
scientific article published on 23 August 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. |
scientific article published on 23 August 2017 |
Statements
1 reference
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. (English)
1 reference
1 reference
1 reference
Thierry Facon
1 reference
Ruben Niesvizky
1 reference
Hartmut Goldschmidt
1 reference
Philippe Moreau
1 reference
Heinz Ludwig
1 reference
Robert Z Orlowski
1 reference
Katja Weisel
1 reference
Vania Hungria
1 reference
Wee-Joo Chng
1 reference
Leonard Minuk
1 reference
Anita Zahlten-Kumeli
1 reference
Douglas Joshua
1 reference
Shibao Feng
1 reference
Amy S Kimball
1 reference
23 August 2017
1 reference
1 reference
18
1 reference
1327-1337
1 reference
10
1 reference
Identifiers
1 reference
1 reference